Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies

Fernando Custodio Fervenza, Peter M. Fitzpatrick, Jim Mertz, Stephen B. Erickson, Scott Liggett, Sandy Popham, Daniel N. Wochos, Arkady Synhavsky, Steven Hippler, Timothy S. Larson, Stephanie M. Bagniewski, Jorge A. Velosa

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Background. Based on its success as a transplant immunosuppressor, there is intense interest in using rapamycin in the treatment of progressive glomerulopathies involving native kidneys. However, we call attention to the potential toxicity associated with the use of rapamycin in this setting. Methods. We conducted a study to examine the efficacy and safety of rapamycin in patients with progressive chronic renal failure. Eleven patients with either focal segmental glomerulosclerosis, immunoglobulin A nephropathy, membranous nephropathy or membrano-proliferative glomerulonephritis and progressive renal failure (defined as an increase in > 25% of baseline serum creatinine over the last year or loss of glomerular filtration rate ≥5 ml/min/year as determined by the Cockcroft-Gault formula), proteinuria ≥1.0 g/24h and with a creatinine clearance of ≥20 ml/min/1.73 m 2 were entered into a 12 month study. Patients were treated with rapamycin, starting at 5 mg/day, orally, aiming for target blood levels of 7-10 ng/dl. All patients were on treatment with an angiotensin-converting enzyme inhibitor and/or an angiotensin receptor blocker, aiming to control blood pressure ≤145/90 mmHg. Results. Six patients developed acute renal failure, defined as an increase in serum creatinine ≥0.5 mg/dl (baseline: 3.2 ± 0.9 mg/dl; peak: 5.6 ± 1.6 mg/dl; P < 0.01, paired t-test). In four patients, discontinuation of the drug resulted in improvement of renal function close to baseline levels. One patient required haemodialysis and had no subsequent recovery of renal function. In another patient, renal function recovered after discontinuation of the drug and then rapamycin was resumed at a lower dose when creatinine returned to baseline. This resulted in a second acute increase in serum creatinine that failed to return to baseline when the medication was discontinued. Four other patients had the following adverse events: skin rash, severe hypertriglyceridaemia, diarrhoea and hyperkalaemia. In none of the subjects were rapamycin levels > 15 ng/dl. Conclusions. Rapamycin can cause nephrotoxicity in some patients with chronic glomerulopathies. Whether the toxicity is solely related to rapamycin, due to the combination of proteinuria and rapamycin, or other unknown factor use is presently undetermined.

Original languageEnglish (US)
Pages (from-to)1288-1292
Number of pages5
JournalNephrology Dialysis Transplantation
Volume19
Issue number5
DOIs
StatePublished - May 2004

Fingerprint

Sirolimus
Kidney
Creatinine
Proteinuria
IGA Glomerulonephritis
Focal Segmental Glomerulosclerosis
Membranous Glomerulonephritis
Angiotensin Receptor Antagonists
Glomerulonephritis
Serum
Glomerular Filtration Rate
Angiotensin-Converting Enzyme Inhibitors
Acute Kidney Injury
Chronic Kidney Failure
Renal Insufficiency
Blood Pressure
Transplants
Safety
Therapeutics

Keywords

  • Acute renal failure
  • Glomerulonephritis
  • Glomerulopathies
  • Nephrotoxicity
  • Rapamycin

ASJC Scopus subject areas

  • Nephrology
  • Transplantation

Cite this

Fervenza, F. C., Fitzpatrick, P. M., Mertz, J., Erickson, S. B., Liggett, S., Popham, S., ... Velosa, J. A. (2004). Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies. Nephrology Dialysis Transplantation, 19(5), 1288-1292. https://doi.org/10.1093/ndt/gfh079

Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies. / Fervenza, Fernando Custodio; Fitzpatrick, Peter M.; Mertz, Jim; Erickson, Stephen B.; Liggett, Scott; Popham, Sandy; Wochos, Daniel N.; Synhavsky, Arkady; Hippler, Steven; Larson, Timothy S.; Bagniewski, Stephanie M.; Velosa, Jorge A.

In: Nephrology Dialysis Transplantation, Vol. 19, No. 5, 05.2004, p. 1288-1292.

Research output: Contribution to journalArticle

Fervenza, FC, Fitzpatrick, PM, Mertz, J, Erickson, SB, Liggett, S, Popham, S, Wochos, DN, Synhavsky, A, Hippler, S, Larson, TS, Bagniewski, SM & Velosa, JA 2004, 'Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies', Nephrology Dialysis Transplantation, vol. 19, no. 5, pp. 1288-1292. https://doi.org/10.1093/ndt/gfh079
Fervenza, Fernando Custodio ; Fitzpatrick, Peter M. ; Mertz, Jim ; Erickson, Stephen B. ; Liggett, Scott ; Popham, Sandy ; Wochos, Daniel N. ; Synhavsky, Arkady ; Hippler, Steven ; Larson, Timothy S. ; Bagniewski, Stephanie M. ; Velosa, Jorge A. / Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies. In: Nephrology Dialysis Transplantation. 2004 ; Vol. 19, No. 5. pp. 1288-1292.
@article{1d9f54c0a38b4757a67e935fc220f010,
title = "Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies",
abstract = "Background. Based on its success as a transplant immunosuppressor, there is intense interest in using rapamycin in the treatment of progressive glomerulopathies involving native kidneys. However, we call attention to the potential toxicity associated with the use of rapamycin in this setting. Methods. We conducted a study to examine the efficacy and safety of rapamycin in patients with progressive chronic renal failure. Eleven patients with either focal segmental glomerulosclerosis, immunoglobulin A nephropathy, membranous nephropathy or membrano-proliferative glomerulonephritis and progressive renal failure (defined as an increase in > 25{\%} of baseline serum creatinine over the last year or loss of glomerular filtration rate ≥5 ml/min/year as determined by the Cockcroft-Gault formula), proteinuria ≥1.0 g/24h and with a creatinine clearance of ≥20 ml/min/1.73 m 2 were entered into a 12 month study. Patients were treated with rapamycin, starting at 5 mg/day, orally, aiming for target blood levels of 7-10 ng/dl. All patients were on treatment with an angiotensin-converting enzyme inhibitor and/or an angiotensin receptor blocker, aiming to control blood pressure ≤145/90 mmHg. Results. Six patients developed acute renal failure, defined as an increase in serum creatinine ≥0.5 mg/dl (baseline: 3.2 ± 0.9 mg/dl; peak: 5.6 ± 1.6 mg/dl; P < 0.01, paired t-test). In four patients, discontinuation of the drug resulted in improvement of renal function close to baseline levels. One patient required haemodialysis and had no subsequent recovery of renal function. In another patient, renal function recovered after discontinuation of the drug and then rapamycin was resumed at a lower dose when creatinine returned to baseline. This resulted in a second acute increase in serum creatinine that failed to return to baseline when the medication was discontinued. Four other patients had the following adverse events: skin rash, severe hypertriglyceridaemia, diarrhoea and hyperkalaemia. In none of the subjects were rapamycin levels > 15 ng/dl. Conclusions. Rapamycin can cause nephrotoxicity in some patients with chronic glomerulopathies. Whether the toxicity is solely related to rapamycin, due to the combination of proteinuria and rapamycin, or other unknown factor use is presently undetermined.",
keywords = "Acute renal failure, Glomerulonephritis, Glomerulopathies, Nephrotoxicity, Rapamycin",
author = "Fervenza, {Fernando Custodio} and Fitzpatrick, {Peter M.} and Jim Mertz and Erickson, {Stephen B.} and Scott Liggett and Sandy Popham and Wochos, {Daniel N.} and Arkady Synhavsky and Steven Hippler and Larson, {Timothy S.} and Bagniewski, {Stephanie M.} and Velosa, {Jorge A.}",
year = "2004",
month = "5",
doi = "10.1093/ndt/gfh079",
language = "English (US)",
volume = "19",
pages = "1288--1292",
journal = "Nephrology Dialysis Transplantation",
issn = "0931-0509",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies

AU - Fervenza, Fernando Custodio

AU - Fitzpatrick, Peter M.

AU - Mertz, Jim

AU - Erickson, Stephen B.

AU - Liggett, Scott

AU - Popham, Sandy

AU - Wochos, Daniel N.

AU - Synhavsky, Arkady

AU - Hippler, Steven

AU - Larson, Timothy S.

AU - Bagniewski, Stephanie M.

AU - Velosa, Jorge A.

PY - 2004/5

Y1 - 2004/5

N2 - Background. Based on its success as a transplant immunosuppressor, there is intense interest in using rapamycin in the treatment of progressive glomerulopathies involving native kidneys. However, we call attention to the potential toxicity associated with the use of rapamycin in this setting. Methods. We conducted a study to examine the efficacy and safety of rapamycin in patients with progressive chronic renal failure. Eleven patients with either focal segmental glomerulosclerosis, immunoglobulin A nephropathy, membranous nephropathy or membrano-proliferative glomerulonephritis and progressive renal failure (defined as an increase in > 25% of baseline serum creatinine over the last year or loss of glomerular filtration rate ≥5 ml/min/year as determined by the Cockcroft-Gault formula), proteinuria ≥1.0 g/24h and with a creatinine clearance of ≥20 ml/min/1.73 m 2 were entered into a 12 month study. Patients were treated with rapamycin, starting at 5 mg/day, orally, aiming for target blood levels of 7-10 ng/dl. All patients were on treatment with an angiotensin-converting enzyme inhibitor and/or an angiotensin receptor blocker, aiming to control blood pressure ≤145/90 mmHg. Results. Six patients developed acute renal failure, defined as an increase in serum creatinine ≥0.5 mg/dl (baseline: 3.2 ± 0.9 mg/dl; peak: 5.6 ± 1.6 mg/dl; P < 0.01, paired t-test). In four patients, discontinuation of the drug resulted in improvement of renal function close to baseline levels. One patient required haemodialysis and had no subsequent recovery of renal function. In another patient, renal function recovered after discontinuation of the drug and then rapamycin was resumed at a lower dose when creatinine returned to baseline. This resulted in a second acute increase in serum creatinine that failed to return to baseline when the medication was discontinued. Four other patients had the following adverse events: skin rash, severe hypertriglyceridaemia, diarrhoea and hyperkalaemia. In none of the subjects were rapamycin levels > 15 ng/dl. Conclusions. Rapamycin can cause nephrotoxicity in some patients with chronic glomerulopathies. Whether the toxicity is solely related to rapamycin, due to the combination of proteinuria and rapamycin, or other unknown factor use is presently undetermined.

AB - Background. Based on its success as a transplant immunosuppressor, there is intense interest in using rapamycin in the treatment of progressive glomerulopathies involving native kidneys. However, we call attention to the potential toxicity associated with the use of rapamycin in this setting. Methods. We conducted a study to examine the efficacy and safety of rapamycin in patients with progressive chronic renal failure. Eleven patients with either focal segmental glomerulosclerosis, immunoglobulin A nephropathy, membranous nephropathy or membrano-proliferative glomerulonephritis and progressive renal failure (defined as an increase in > 25% of baseline serum creatinine over the last year or loss of glomerular filtration rate ≥5 ml/min/year as determined by the Cockcroft-Gault formula), proteinuria ≥1.0 g/24h and with a creatinine clearance of ≥20 ml/min/1.73 m 2 were entered into a 12 month study. Patients were treated with rapamycin, starting at 5 mg/day, orally, aiming for target blood levels of 7-10 ng/dl. All patients were on treatment with an angiotensin-converting enzyme inhibitor and/or an angiotensin receptor blocker, aiming to control blood pressure ≤145/90 mmHg. Results. Six patients developed acute renal failure, defined as an increase in serum creatinine ≥0.5 mg/dl (baseline: 3.2 ± 0.9 mg/dl; peak: 5.6 ± 1.6 mg/dl; P < 0.01, paired t-test). In four patients, discontinuation of the drug resulted in improvement of renal function close to baseline levels. One patient required haemodialysis and had no subsequent recovery of renal function. In another patient, renal function recovered after discontinuation of the drug and then rapamycin was resumed at a lower dose when creatinine returned to baseline. This resulted in a second acute increase in serum creatinine that failed to return to baseline when the medication was discontinued. Four other patients had the following adverse events: skin rash, severe hypertriglyceridaemia, diarrhoea and hyperkalaemia. In none of the subjects were rapamycin levels > 15 ng/dl. Conclusions. Rapamycin can cause nephrotoxicity in some patients with chronic glomerulopathies. Whether the toxicity is solely related to rapamycin, due to the combination of proteinuria and rapamycin, or other unknown factor use is presently undetermined.

KW - Acute renal failure

KW - Glomerulonephritis

KW - Glomerulopathies

KW - Nephrotoxicity

KW - Rapamycin

UR - http://www.scopus.com/inward/record.url?scp=2442442944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442442944&partnerID=8YFLogxK

U2 - 10.1093/ndt/gfh079

DO - 10.1093/ndt/gfh079

M3 - Article

C2 - 15102967

AN - SCOPUS:2442442944

VL - 19

SP - 1288

EP - 1292

JO - Nephrology Dialysis Transplantation

JF - Nephrology Dialysis Transplantation

SN - 0931-0509

IS - 5

ER -